ROME, AUG 19 - An Italo-US team of scientists have made a breakthrough in the early diagnosis of amyotrophic lateral ...

The ALS therapy ATH-1105 entered the brain and spinal cord at dose-proportional levels in healthy volunteers, and had a good ...

Neurizon Therapeutics has reported positive topline results from an open-label extension study of its lead candidate NUZ-001 ...

By analyzing millions of messenger RNA molecules (mRNA) during the course of ALS, researchers at Stockholm University, in ...

Yet another biotech is facing a delay from the FDA as the agency reels from intense staffing cuts. | Yet another biotech is ...

Amyotrophic lateral sclerosis, or ALS, attacks nerve cells known as motor neurons in the brain and spinal cord, gradually leading to paralysis. The loss of function of an important gene, C9orf72 ...

Raffaella Uccelli, Alessandra Binazzi, Pierluigi Altavista, Stefano Belli, Pietro Comba, Marina Mastrantonio, Nicola Vanacore, Geographic distribution of amyotrophic lateral sclerosis through motor ...

Stanford University scientists have developed a brain implant designed to "hear" and vocalize words a person with severe ...

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease predominantly affecting upper and lower motor neurons. Here, the authors outline previous and current efforts to characterize ...

• Key Amyotrophic Lateral Sclerosis Pipeline Therapies: ION363, FB418, SRK-015, RNS60, QRL-201, SAR443820, MN-166, VM202, VRG-50635, Zilucoplan, and others.

Amyotrophic lateral sclerosis, known as ALS, is a neurodegenerative disorder which affects motor neurons. These are the neuronal cells responsible for muscle innervation, whose degenerations leads ...